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Interactions of LDL and modified LDL with mesangial cells and matrix.
Hyperlipidemia may play a role in the progression of diabetic and other
renal diseases. Low density lipoprotein (LDL) and other proteins
including extracellular matrix components undergo nonenzymatic gly-
cation in vivo. We examined the effects of glycation of LDL as occurs
in diabetes (4 to 8%) on binding and uptake by mesangial cells and their
proliferation. The glycation of LDL (g-LDL) significantly decreased its
binding and uptake by mesangial cells by 15 to 20%, indicating that
glycated LDL binds to the LDL receptor, but with lower affinity than
LDL. Both LDL and g-LDL modestly stimulated [3H] thymidine
incorporation into mesangial cells at 5 to 10 g/ml. Native, oxidized
(Ox-LDL) and glycated LDL all bound to the extracellular matrix
generated by rat mesangial cells in culture. The binding of LDL,
Ox-LDL and g-LDL to mesangial matrix was two to four times higher
than to mesangial cells. Binding of LDL and g-LDL was significantly
higher to glycolaldehyde modified matrix, which serves as an in vitro
model for nonenzymatic glycation end-product cross-linking of matrix
which occurs in long-standing diabetes. Based on these findings, we
propose that glycation of LDL decreases its binding and uptake by the
LDL receptor of mesangial cells and may slow its catabolism. Further-
more, LDL bound to extracellular mesangial matrix can undergo
oxidation and generate cytotoxic LDL components. This process may
be further enhanced by advanced glycation of the mesangial matrix in
diabetes, contributing to glomerular pathology.
Lipid deposits can be found in the glomeruli and renal
interstitium of patients with diabetic nephropathy as well as in
a variety of other renal diseases [1—5]. This has renewed interest
in the possibility that hyperlipidemia and abnormalities in lipid
metabolism may contribute to the progression of renal disease,
including diabetic nephropathy [6—15]. Hyperglycemia also
results in nonenzymatic glycation of various proteins in vivo
including hemoglobin, albumin and apolipoprotein B of LDL
[16—18]. Diabetic patients have higher levels of glycated LDL
than their euglycemic counterparts (2 to 8% vs. 1 to 2%,
respectively) and a significant correlation exists between glyce-
mic control and the extent of LDL glycation [19]. Glycation of
lysine residues of apolipoprotein B of LDL has been shown to
alter its cellular uptake and metabolism [20—24]. Steinbrecher
and Witztum have demonstrated that glycation of LDL slows
its degradation by fibroblasts and inhibits its clearance in guinea
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pigs [22]. Triau, Arbetter and Schaefer reported a correlation
between the extent of LDL glycation and the degree of inhibi-
tion of binding, uptake and degradation of LDL in Hep G2 cells
[24]. In other studies, Schleicher et al failed to demonstrate
significant changes in the catabolism of moderately glycated
LDL by fibroblasts, endothelial cells, hepatocytes and macro-
phages [25]. Recently, we and others have demonstrated recep-
tor mediated uptake of LDL by mesangial cells [26, 27]. In
addition, we found that oxidative modification of LDL in-
creased its uptake by mesangial cells [28], showing that modi-
fications of LDL can alter its metabolism by mesangial cells
[28—30].
LDL and modified LDL may also bind to extracellular matrix
components of the vascular wall [31—33]. LDL binds to proteo-
glycans and collagen in vitro, and apolipoprotein B has been
found extracellularly by immuno- and histochemical techniques
[34-36]. In addition, proteoglycan-lipoprotein complexes have
been extracted from fatty streak and fibrous plaques of athero-
matous lesions [37, 38]. The trapping of LDL in the extracellu-
lar matrix may also be influenced by the character of the matrix.
Collagen undergoes nonenzymatic glycation with normal aging,
eventually resulting in the generation of advanced glycation end
products [18]. This process occurs in an accelerated fashion in
tissues of diabetic patients and is thought to contribute to the
accumulation of extracellular matrix in diabetes [18]. Enhanced
binding of albumin, insulin, fibrinogen and IgG has been de-
scribed after nonenzymatic glycation of glomerular basement
membrane material [17], and has been related to trapping of
these proteins in the glomeruli of patients with diabetic
nephropathy. Similarly Brownlee, Vlassara and Cerami [39]
showed that collagen, after in vitro nonenzymatic glycation,
bound LDL to a greater extent than unmodified collagen.
Binding of LDL to glycated matrix components could lead to
accumulation of LDL in the subendothelial space, where the
LDL could be oxidized and form vascular sclerotic lesions [20].
Because of the fenestrated glomerular endothelium [41], LDL
has access to the mesangium so that the possibility of LDL
trapping in the mesangial matrix has to be considered as a
contributory factor to the development of renal lesions in
hyperlipidemia and diabetes mellitus.
The purpose of the present study was to compare the binding
and uptake of native and nonenzymatically glycated LDL by
mesangial cells and to determine the resulting effects on mesan-
gial cell growth. In addition, we examined binding of native,
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glycated and oxidatively modified LDL to mesangial matrix
generated in culture and the effects of nonenzymatic glycation
of matrix on these interactions. Our studies demonstrate that
glycation of 8% of lysine residues on apolipoproteins of LDL
decreases binding, uptake and subsequent cellular metabolism
of LDL by mesangial cells by 15 to 20%. Binding of native,
glycated or oxidized LDL to extracellular matrix of cultured
mesangial cells exceeded that to intact cells several-fold, but
was comparable among the different LDL preparations. Ad-
vanced nonenzymatic glycation of matrix enhanced the binding
of LDL and g-LDL but not that of oxidized LDL to modified
mesangial matrix.
Based on these results, we hypothesize that during hyperlip-
idemia and diabetes, LDL could be trapped by extracellular
matrix in the kidney and specifically in the mesangium. Oxida-
tive modification of this accumulated LDL, as might occur
locally, could then contribute to the pathophysiology of giomer-
uloscierosis.
Methods
Materials
Carrier free !25I1 sodium, [3H} thymidine and ['4C1 glucose
were obtained from Amersham (Arlington Heights, Illinois,
USA). RPM! 1640, penicillin-streptomycin and fetal calf serum
were obtained from Flow Laboratories (McLean, Virginia,
USA). Nu serum and Dulbecco's phosphate buffered saline
were purchased from Gibco Laboratories. Fatty acid free
bovine serum albumin was from Sigma Chemical Co. (St.
Louis, Missouri, USA). Enzymobeads were from Biorad (Rich-
mond, California, USA).
Albumin bound ['4Cj oleate was prepared by the method of
Van Harken, Dixon and Heimberg [42]. ['4C1 Oleic acid was
obtained from Amersham (52 mCi/mmol) and evaporated to
dryness and dissolved in 10 ml of 0.9% NaCI (pH 7.4) contain-
ing 0.1 g/ml of BSA. Aliquots were stored at 0°C until use in
experiments.
Cell culture
Mesangial cells were isolated from male Sprague-Dawley rats
(Charles River Breeders, Wilmington, Massachusetts, USA),
which weighed 75 to 100 grams, and were maintained on tap
water and Purina Rat Chow ad libitum. Kidneys were removed
under pentobarbital anesthesia. The glomeruli were isolated
and cultured as previously described [43]. Culture medium
consisted of RPMI 1640 supplemented by 20% fetal calf serum
with added penicillin and streptomycin. Once confluent (15 to
20 days after glomerular isolation), the mesangial cells were
then subcultured at two to three week intervals. Mesangial cells
from 4th to 7th subculture were used for all experiments.
Preparation and labeling of lipoproteins
Lipoproteins were prepared from normolipidemic fasting
volunteers. After the addition of 0.02% EDTA and 0.05%
Na-azide to the plasma, LDL (d 1.019 to 1.063) was prepared by
sequential ultracentrifugation at 15°C [441. Solid KBr was used
for density adjustment. The lipoprotein was recentrifuged at d
= 1.063 and dialyzed for 24 hours at 4°C against 150 mi NaCl,
1 mM NaHCO3, pH 7.5 containing 0.01% azide and 0.02%
EDTA. Protein concentrations were determined by the Lowry
method. LDL, oxidized LDL, and glycated LDL were radiola-
beled with [12511 using the Enzymobead method (Biorad), which
utilizes a lactoperoxidase and glucose oxidase. [1251] LDL was
separated from unincorporated [125J] by Sephadex gel filtration.
The labeled lipoproteins were dialyzed for 24 hours at 4°C. TCA
precipitability usually exceeded 90%. LDL was dialyzed to
remove EDTA and oxidized with Cu (10 jiM) at 30°C for 18
hours, as reported before [28].
Glycation of LDL
LDL (I to 3 mg/mI) was incubated with or without 200 mi'vt
glucose in PBS pH 7.4, for 12 to 14 days at 20°C, with 0.05%
EDTA [45, 461, Aprotinin, PMSF and gentamicin. The incuba-
tion mixture was filter sterilized using a 0.22 jim filter. The
extent of glycation was determined by incubating LDL (1 to 3
mg/ml) with ['4C]-glucose (286 mCi/mmol) and 200 m glucose.
['4C]-glucose was purified by thin layer chromatography, prior
to use in glycation experiments to remove reactive contami-
nants [471. Aliquots (50 jd) were taken in duplicate on serial
days, and the amount of radioactivity incorporated into the
LDL was determined after TCA precipitation and expressed as
percentage of lysine residues glycated per mmol of LDL [161.
Control LDL samples were incubated in parallel in PBS in the
absence of glucose.
Binding and uptake of lipoproteins by mesangial cells
Mesangial cells (4th to 7th subculture) were plated onto
24-well cell culture plates (Nunc) at 20,000 cells/ml and grown
in RPM! with 5% fetal calf serum (FCS) to confluence, usually
five days. Media were then changed for 36 hours to lipoprotein
deficient media which consisted of RPMI, 8% Nu serum and 1%
penicillin/streptomycin. Prior to binding experiments, the cells
were kept at 4°C for 20 minutes, the media removed and
replaced by Dulbecco's phosphate buffer solution with 1 m
Ca, 100 mg% glucose and 1 mg/ml BSA. Labeled LDL,
Ox-LDL or g-LDL (2 jig/ml) were then added alone or in the
presence of increasing concentrations of unlabeled lipoproteins
or the various additions presented in the results. In preliminary
experiments, binding studies were performed from 0 to 120
minutes and showed equilibrium after 90 to 120 minutes. All
subsequent experiments were performed for two hours at 4°C,
after which the media were removed and the cells washed three
times with 2 ml of ice-cold PBS that contained 1% BSA. After
a final wash with PBS, 0.5 ml of 1 N NaOH was added to each
well to dissolve the cells. After 24 hours at room temperature
the dissolved cells were collected and each well was washed
with 0.5 ml 1 N NaOH. Cell associated radioactivity was then
measured in a gamma counter. Cell protein was determined
using Lowry method.
Uptake studies of lipoproteins were performed as described
above, except that studies were performed at 37°C from 0 to 120
minutes.
['4C] oleate incorporation into cholesteryl esters
For [4C] oleic acid incorporation into cholesterol oleate,
mesangial cells were placed in 9.6 cm2 tissue culture wells at
approximately 5 x l0 cells/well in RPMI-1640 supplemented
with 10% fetal calf serum and 1% penicillinlstreptomycin. After
five days media were replaced with 8% Nu serum in RPMI 1640
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media for 16 hours, and ['4C] oleic acid (177 1.d of the BSA-
saline solution, prepared as above) was then added to the wells,
together with either RPM! with LDL (100 g/ml) or RPM! with
g-LDL (100 jsg/ml) or RPMI only. After two hours of incubation
at 37°C in 5% C02, media were removed and the wells washed
twice with PBS. Lipids were extracted using 2 ml petroleum
ether: 2-propanol (3:2) for 30 minutes at room temperature. The
wells were rinsed once with 1 ml and the wash added to the
original extract. The extracts were evaporated under nitrogen
and the lipids resuspended in 150 sl chloroform. The lipids were
spotted on silica gel thin layer chromatography plates which
were then developed in hexane-ethyl ether-acetic acid (90:20: 1,
vollvol/vol). Cholesterol and cholesterol oleate were run as
standards, After exposure to iodine vapor for visualization,
autoradiography was performed and then the ester bands were
scraped into separate tubes. Two ml of 1 N ethanolic KOH was
added and lipids saponified at 80°C for one hour [48]. Four ml
Hexane and 1.5 ml water were added and the tubes were shaken
and centrifuged to separate the phases. An aliquot of the lower
ethanol/water phase was transferred to a scintillation vial and
the radioactivity determined in a scintillation counter. The
counts in the ethanol/water phase represent the incorporation of
oleic acid into cholesterol esters, an index of the rate of
cholesteryl ester formation. The uptake of LDL and g-LDL was
calculated by subtracting the oleate esterification seen in
mesangial cells that had been incubated in parallel, but without
lipoproteins in the media.
Oxidation of LDL and g-LDL by mesangial cells or by
copper
Mesangial cells were grown in six-well culture plates until
confluent. The media were then changed to RPM! with 8% Nu
serum and 1% penicillin (100 s/ml) and streptomycin (100
sg/ml). After 36 hours all wells were washed twice with PBS.
Media containing LDL or g-LDL (100 ig/ml) in a balanced salt
solution with 1TS and penicillin/streptomycin were then added
to the wells and incubated for 24 hours. Aliquots of 1 ml were
removed at 0, 8, and 24 hours and EDTA (0.02%) was added to
prevent further oxidation. For copper-catalyzed oxidative mod-
ification, the LDL or g-LDL (100 sg/ml) was incubated with 10
sM Cu at 20°C. Aliquots were removed at 0 and 24 hours and
EDTA was added to prevent further oxidation. The samples
were then concentrated using Centricon 10 microconcentrators.
Oxidation of LDL was determined by TBARS assay and
agarose gel electrophoresis.
Determination of LDL oxidation by thiobarbituric acid
reactive substances (TBARS) and agarose gel electrophoresis
As a measure of LDL oxidation thiobarbituric acid reactive
substance (TBARS) content was determined for the LDL
preparations according to a published method [491. One ml of
20% TCA was added to 100 d sample containing 50 to 100 g
of the lipoprotein. This was followed by the addition of 1 ml of
1% thiobarbituric acid and incubation for 45 minutes at 90°C.
After cooling, the samples were centrifuged at 1000 x g at 20°C
for 20 minutes and the absorbance of the supernatants was
determined at 532 nm. Data are expressed as malondialdehyde
(MDA) equivalents in nmol/mg LDL protein. Tetramethoxy-
propane was used as a standard. Our preparations of control
LDL and glycated LDL contained no detectable TBARS.
Changes in electrophoretic mobility on agarose gels (0.7% gel)
were also used to analyze the LDL preparations [50].
Cell proliferation studies
Mesangial cells were plated in 96 well plates at approximately
20,000 cells/mI and maintained for five days until confluent in
RPMI containing 10% fetal calf serum and 1% penicillin!
streptomycin. The media were then changed to lipoprotein
deficient media (as above) for 24 to 36 hours and each well was
washed with PBS. Fresh media containing 1 Ci/ml of [3H]
thymidine and increasing concentrations of LDL or g-LDL
were added and the cells incubated for 24 hours. The cells were
then washed with PBS, trypsinized for one hour and harvested
by a PHD cell harvester (Cambridge Technology, !nc.). Radio-
activity associated with cellular DNA was measured in a
scintillation counter and reflects cell proliferation. Determina-
tions were performed in triplicate or quadruplicate for each
experiment. We also employed the colorimetric assay of meth-
ylene blue incorporation into cells as an additional method to
determine cell number [51]. Cells were grown in 96 well plates
as described above and incubated with varying amounts of LDL
or g-LDL for a total of 72 hours. Cell numbers were determined
in triplicate or quadruplicate by measuring the optical density at
650 nm, after incubation with methylene blue and three washes,
in a 96-well plate spectrophotometer reader (Titertek Multi-
skan). A standard curve prepared by serial dilutions of mesan-
gial cells (from 40,000 to 2,000) on 96 well plates allowed
conversion of the OD readings to direct cell numbers.
Generation of mesangial matrix
Cells were grown for two weeks in 24-well tissue culture
plates with media changed twice a week. After removal of
media the cell layer was dissociated from the matrix by three
minute exposure to 0.25 mi NH4OH/0. 1% Triton X followed
by washing three times with PBS, and once with dH2O.
Insoluble matrix remained in the tissue culture wells, as previ-
ously described in detail [52]. This matrix consisted of collagen
(type I and IV), laminin, fibronectin and glycosaminoglycans
[52]. The amount of matrix remaining in the wells varied by less
than 10% within a series of experiments, but could vary up to
50% between different series of experiments. The latter may be
due to differences with length of culture (12 to 16 days) and
different subcultures used to generate the matrix.
Nonenzymatic glycation of matrix
Modifications of the matrix were performed as previously
reported [52]. Native matrix prepared as described above was
incubated under sterile conditions either for two weeks with 500
m glucose, or for 24 hours with 50 mivi glycolaldehyde. All
incubating solutions were made up in 0.2 M NaHPO4 buffer
solution, pH 7.8. Glycolaldehyde resulted in a highly reactive
fragmentation product of protein glycosylation which cross-
links protein amino groups at a much faster rate than occurs
with glucose in advanced nonenzymatic glycation end-product
formation [52]. The control condition consisted of matrix incu-
bated with 0.2 M NaHPO4 buffer solution alone for either two
weeks or for 24 hours. The glycating solutions were then
aspirated. In the case of glycolaldehyde modification, the
matrix was then incubated with 1 M glycine ethyl ester, pH 8.0,
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Days 2 4 7 10 14
% Lysine
Residues 2.2 2.9 3.4 5.4 8.4
Glycated 0.2 0.3 0.3 1.2 1.4
for one hour in order to substitute any remaining free carbonyl
groups. All matrices were then washed three times with PBS,
and once with dH2O. The degree of glycation and advanced
glycation end-product formation resulting from this treatment
have been reported by us previously [521.
Binding of LDL, Ox-LDL, g-LDL to regular and modified
matrix
[12511 labeled LDL, Ox-LDL and g-LDL (at the concentra-
tions indicated) were incubated with the different matrix prep-
arations at 4°C for two hours as described for the binding
experiments with mesangial cells. After washing three times
with 1% BSA and twice with PBS, the matrix was dissolved in
1 N NaoH and radioactivity measured.
Statislical evaluation
Results are reported as means 5EM. The means of the
duplicate, triplicate or quadruplicate determinations from each
experiment served as a single experiment. Comparison was
performed by paired or unpaired Student's t-test, as appropri-
ate.
Results
Glycation of LDL
To evaluate the degree of LDL glycation achieved in vitro,
LDL was incubated with ['4C1-glucose, and glucose incorpora-
tion into LDL was determined after various times of incubation.
EDTA and protease inhibitors were included to prevent degra-
dation of LDL during in vitro incubation [45]. As shown in
Table 1, increasing amounts of glucose were incorporated into
LDL over a two week period, so that approximately 8% of
lysine residues of LDL were glycated after two weeks. No
oxidation of LDL was detected by measuring TBARS and there
was no difference in electrophoretic mobility on agarose gel
electrophoresis between the control and glycated LDL (not
shown).
Binding of native and glycated LDL to mesangial cells
Binding of [125j] LDL and [12511 g-LDL to mesangial cells was
determined in three series of experiments after two hours at 4°C
in the presence of increasing concentrations of unlabeled LDL
and g-LDL, respectively (Fig. 1). Increasing concentrations of
unlabeled LDL resulted in progressive competition for the
binding of labeled LDL. Binding of [12511 g-LDL was also
competed for by increasing concentrations of unlabeled g-LDL,
but to a lesser extent than in the case of LDL (Fig. 1). In a series
of five experiments, binding at 2 jsg/ml was 6.9 1.0 ng/l00 jig
cell protein for LDL and 5.9 0.9 ng/lOO jig cell protein for
g-LDL (P C 0.01) and the specific binding (determined at
50-fold excess of unlabeled LDL or g-LDL) were 4.6 0.9
ng/l00 jig cell protein and 1.8 0.4, respectively (P C 0.05).
We also determined if binding of LDL or g-LDL could be
competitively inhibited in a crossover manner by a 50-fold
excess of g-LDL or LDL, respectively. While g-LDL (45%
competition) was less effective in competing for LDL binding
than LDL itself (55% competition), excess LDL competed for
binding of g-LDL to a higher extent (55%) than g-LDL (40%;
Fig. 1). These findings are consistent with both LDL and g-LDL
binding to a common binding site, with g-LDL having a lower
affinity than LDL.
Uptake of native and glycated LDL by mesangial cells
Uptake of both LDL and g-LDL increased with time over a
two hour incubation at 37°C (Fig. 2). Uptake of LDL and
g-LDL was further examined by determining the incorporation
of ['4C] oleate into mesangial cell cholesteryl esters after
exposure to LDL or g-LDL [53j, LDL uptake results in
cholesterol delivery to the cell, which is then esterified, so that
esterification of cholesterol can be used as an index of LDL
uptake [531. Consistent with the decreased binding of g-LDL as
compared to LDL observed at concentrations of 2 jiglml,
pretreatment of mesangial cells with g-LDL (100 jsg/ml) also
resulted in lower ["C] oleate incorporation into cellular cho-
lesteryl esters than pretreatment with LDL (LDL: 85 12;
g-LDL 62 12 pmol ['4C] oleate incorporated per mg cell
protein; N = 4 paired experiments; P C 0.05). Taken together
Table 1. Glycation of LDL. with 200 mivi ('4C) glucose
Data are presented as means 5EM of 3 experiments, each performed
in duplicate.
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FIg. 1. Competition binding curves for [125)] LDL and ['25Jj g-LDL by
mesangial cells. Mesangial cells were incubated for 2 hours at 4°C with
[12511 LDL (2 jig/mI) and increasing concentrations of unlabeled LDL(•) or with [1251] g-LDL (2 jig/mI) and increasing concentrations of
unlabeled g-LDL (0). Glycation of LDL was performed as detailed in
Methods and averaged 8%. Binding is expressed as ng of [1251] labeled
lipoprotein bound per 100 jig cell protein. Results represent means
5EM of three experiments, each done in duplicate. In addition, compe-
tition binding was performed in a crossover manner for [1251] LDL with
100 jig of unlabeled g-LDL (U) and for [125j] g-LDL with 100 jig
unlabeled LDL (U).
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Time, minutes
Fig. 2. Time course of uptake of['25!J LDL (0) and [I2sjjgLDL(•) by
mesangial cells. Mesangial cells were incubated at 37°C with [12511 LDL
(2 sg/ml) or [1251] g-LDL (2 gIml) for the indicated times and uptake
was evaluated as described in Methods. Each value represents the
means SEM of two experiments, each carried out in duplicate.
these results show decreased binding and uptake of g-LDL as
compared to LDL by mesangial cells.
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Fig. 3. A. Effect of LDL (--0--) or g-LDL (—•—) on [3H] thymidine
incorporation by mesangial cells. Thymidine incorporation into mesan-
gial cells was determined in the presence of increasing concentrations of
LDL or g-LDL during 24 hours of culture. Results represent [3H}
thymidine incorporated per well on 96 well plates and are means SEM
of four experiments, each carried out in triplicate or quadruplicate. B.
Effect of LDL or g-LDL on mesangial cell number as measured by
methylene blue uptake assay. Methylene blue uptake by viable mesan-
gial cells was determined in the presence of increasing concentrations of
LDL or g-LDL after a 72-hour culture period, The results are means
SEM of three experiments, each carried out in quadruplicate.
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Cell proliferation studies
The effects of increasing amounts of LDL and g-LDL on
mesangial cell proliferation were determined by [3H]-thymidine
incorporation after 24 hours and by cell number after 72 hours
of incubation. As shown in Figure 3A, both LDL and g-LDL
resulted in a slight stimulation of [3H] thymidine incorporation
at 5 to 10 sg/ml concentration, whereas 100 g/ml of LDL or
g-LDL were associated with slight inhibition. Consistent with
the enhanced [3H] thymidine incorporation there was a slight
increase in cell number with lower (5 to 10 g/ml) concentra-
tions of either LDL or g-LDL, but no changes were noted at
higher concentrations (Fig. 3B). There were no differences in
the effects of LDL and g-LDL on the number of mesangial cells
at any of the concentrations tested.
Oxidation of LDL and g-LDL
We and others have previously shown that oxidation of LDL
renders it cytotoxic to mesangial cells [28, 30]. We examined
the possibility that LDL or g-LDL could be oxidized during
incubation with mesangial cells. LDL and g-LDL were incu-
bated with cells at 37°C, and oxidation was determined at
various time points by TBARS assay and agarose gel electro-
phoresis. Both LDL and g-LDL were extensively oxidatively
modified during the 24 hour incubation, to 14 and 11 nmoles
TBARS per mg LDL protein after eight hours and 19 and 12
nmols after 24 hours, respectively. Furthermore LDL and
g-LDL could be modified to a similar degree (38 and 37 nmoles
TBARS) in a cell-free incubation in the presence of 10 M
Cut The oxidation of LDL and g-LDL was also associated
with an increase in their electrophoretic mobility on agarose gel
(not shown). Thus both LDL and moderately glycated LDL can
be oxidatively modified.
Binding of LDL, g-LDL, or Ox-LDL to mesangial matrix
The matrix generated by rat mesangial cells was prepared in
24 well plates and binding studies were performed with [12511
labeled LDL and g-LDL (2 p.g/ml) for two hours at 4°C. The
binding of [1251] LDL was 26 2 and that of [12511 g-LDL 27
6 ng/well (Fig. 4A). Each of the 24 wells contained about 10 g
of matrix protein. Comparison of LDL or g-LDL binding to
intact mesangial cells in 24 well cultures or to matrix remaining
in these wells after cell removal shows that at concentrations of
2 jsg/ml the binding of [125!] LDL and [125J] g-LDL to mesangial
matrix is comparable, but is three to four times higher than that
to mesangial cells (Fig. 4A). At 100 g/ml of LDL or g-LDL
binding to matrix is even higher, but not different for LDL or
g-LDL (283 44 pg/well vs. 267 44; N = 3). It should be
noted that in binding studies with intact mesangial cells in
culture, the mesangial matrix is covered by the mesangial cells
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Fig. 5. Concentration dependent binding of '23jj LDL (0) and 125jj
ox-LDL (•) to mesangial matrix. Results are means SEM from 4
experiments each done in duplicate.
Table 2. Binding of LDL, OxLDL or gLDL to unmodified, glucose
or glycolaldehyde modified matrix (ng/well)
gLDL LDL OxLDL
N
Unmodified matrix
Glucose modified matrix
P
6
20 1
12 1
<0.01
39 10
40 13
NS
8
59
47
NS
20
20
N
Unmodified matrix
Glycolaldehyde modified
matrix
P
4
44 11
60 9
<0.02
30 2
73 13
<0.02
6
34
39
NS
9
7
Fig. 4. Comparison of binding off'25!] labeled LDL and g-LDL (A) or
LDL and Ox-LDL (B) to mesangial cells (•) or matrix () at 4°C.
Mesangial matrix was prepared by removal of cells with a detergent-
lysis buffer as detailed in Methods. Culture plates with intact cells or
matrix only were then incubated with either [1251] LDL, [12511 Ox-LDL
or [12511 g-LDL at concentrations of 2 sg/ml for two hours at 4°C and
binding determined as described in Methods. Binding is expressed as
[125!] labeled LDL Ox-LDL on g-LDL bound to cells or to matrix from
comparable culture wells. Results are means SEM from the number of
indicated experiments, each carried out in duplicate.
growing on it, and only after removal of these cells does the
underlying matrix become accessible for LDL binding.
Comparison of the binding of [1251] LDL and [125j] Ox-LDL
to cells and matrix were performed similarly. At concentrations
of 2 rg/ml, the binding of LDL to matrix was 35 6 ng/well and
that of Ox-LDL 49 12 nglwell (Fig. 4B), values not signifi-
cantly different from each other, In four experiments, we also
performed concentration dependent binding of [125!] LDL or
[12511 Ox-LDL (from 2 to 100 rg/ml) to matrix (Fig. 5). The
concentration dependent binding of both LDL and Ox-LDL
was not saturable, indicating that the interactions of LDL with
the matrix are not to specific binding sites but are nonspecific.
At a concentration of 100 g/ml, the binding of Ox-LDL to
mesangial matrix significantly exceeded that of LDL (LDL: 222
34 ng/well vs. Ox-LDL: 836 211 ng/well; N = 7 paired
experiments, P < 0.02), consistent with reports of enhanced
trapping of Ox-LDL as compared to LDL in collagen gels [32].
Binding ofLDL, Ox-LDL and g-LDL to glucose and
glycolaldehyde modified matrix
Binding studies were similarly performed with different LDL
preparations and matrix modified in vitro by either glucose or
glycolaldehyde. The binding of [125!] LDL to unmodified and
glucose modified matrix was comparable at 39 10 and 40 13
ng/well, and that of [12511 Ox-LDL 59 20 and 47 20 ng/well,
respectively (Table 2). Binding of g-LDL to unmodified and
glucose modified matrix was 20 1 and 12 1 ng/well,
respectively (Table 2). Thus, glucose modification of mesangial
matrix for two weeks had no effect on binding of either LDL or
Ox-LDL, and slightly decreased that of g-LDL. The two week
in vitro incubation of matrix with 500 m glucose may not
result in a comparable degree of advanced nonenzymatic gly-
cation end-product formation, as is observed in vivo in diabetes
after decades of hyperglycemia [18]. We therefore modified
matrix with a highly reactive cross-linker, glycolaldehyde,
which is thought to mimic formation of advanced glycation
end-products [18]. The binding of LDL to glycolaldehyde
modified matrix significantly exceeded that to unmodified ma-
trix (73 13 ng/well versus 30 2; N = 6 paired experiments;
P < 0.02). Similarly, binding of g-LDL to glycolaldehyde
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modified matrix significantly exceeded that to unmodified ma-
trix (Table 2). In contrast, glycolaldehyde modification of
mesangial matrix did not influence the binding of Ox-LDL
(Table 2).
Discussion
Abnormalities in lipid metabolism and nonenzymatic glyca-
tion of proteins may contribute to the development of acceler-
ated atherosclerosis and nephropathy occurring in patients with
diabetes [1, 2, 18]. Our results show that glycation of LDL
modestly decreases binding and uptake by mesangial cells.
Furthermore, the extracellular mesangial matrix is capable of
binding considerable amounts of LDL or modified LDL. Cross-
linking of matrix with glycolaldehyde, mimicking the generation
of advanced nonenzymatic glycation end-products, further en-
hanced binding of LDL, which is consistent with the hypothesis
that LDL can be trapped in the mesangial matrix of patients
with diabetes mellitus.
Apolipoprotein B of LDL, like other serum and matrix
proteins, undergoes nonenzymatic glycation in vivo [16, 18, 19].
Our present results with mesangial cells are consistent with
results that demonstrate that even modest glycation (8%) of
LDL can decrease the binding affinity and uptake of LDL. The
results of competitive binding studies with LDL and g-LDL to
mesangial cells are consistent with both LDL and g-LDL
binding to the LDL receptor with a reduced affinity for g-LDL.
While g-LDL binds to the LDL receptor, it is apparently not
recognized by the scavenger receptor for Ox-LDL, as oxidized
LDL binds to and is taken up by mesangial cells to a greater
extent than native LDL [28]. Since the catabolism of glycated
LDL is slowed, it could locally accumulate, eventually be
oxidized [49, 54] and thus contribute to injury of the vascular
wall and the kidney. Furthermore, hyperglycemia may enhance
lipid peroxidation [45, 46] which would accelerate this process.
In cell culture, including mesangial cells, low concentrations
of LDL enhance cell proliferation [28]. On the other hand, even
low concentrations of oxidized LDL are cytotoxic to cells,
including mesangial cells [28—30]. Potential effects of LDL
glycation on cell proliferation have not been reported. We
therefore also examined the effect of g-LDL on the proliferative
activity of mesangial cells in culture. Both LDL and g-LDL
slightly stimulated mesangial cell proliferation at low concen-
trations (5 to 10 tg/ml) but were without effect at higher
concentrations. It should be noted that our studies were carried
out across species, that is, using human LDL and rat mesangial
cells. Thus concentration dependent effects of LDL on human
cells might differ in the degree, but not direction of change.
LDL is not only taken up by cells, but also binds to
extracellular matrix components which would contribute to the
pathogenesis of atherosclerosis and glomerulosclerosis. The
possibility of LDL being trapped in the extracellular matrix is
particularly intriguing in the case of the glomerular mesangium.
Because of the fenestrated glomerular endothelium [41] and the
absence of intervening basement membrane, macromolecules,
including LDL, have relatively unimpaired access to the mesan-
gium. Their accumulation in the mesangium will, therefore,
depend on their concentration in the glomerular circulation,
their uptake by mesangial cells, their outflow from the mesan-
gium and finally their binding to mesangial matrix. In order to
study the interactions of LDL with mesangial matrix we have
developed an in vitro model of matrix generated by cultured
mesangial cells [521. After removal of cells by a lysis-detergent
solution, insoluble material remains, which contains at least
collagen type I and IV, fibronectin, laminin and glycosamino-
glycans [52]. Using this model, we could now demonstrate that
LDL, g-LDL and Ox-LDL all bind to a considerable extent to
this matrix.
Our system allowed us to not only examine the potential
effects of LDL modification, but also those of matrix modifica-
tion on the binding of different LDL preparations. As previ-
ously reported by us, incubation of matrix with high glucose or
highly reactive glycolaldehyde results in the formation of mod-
erate (with glucose), or extensive (with glycolaldehyde)
amounts of fluorophores which indicate the presence of ad-
vanced glycation end-products [18, 52]. The binding of either
native LDL or Ox-LDL was not significantly altered when
matrix was modified by glucose in vitro. However, LDL
binding to glycolaldehyde-modified matrix was significantly
enhanced, consistent with the postulate that advanced glycation
can enhance trapping of proteins in the mesangium [551. Based
on our present results and previous reports [26, 281, a contri-
bution of hyperlipidemia to glomerulosclerosis can be envi-
sioned that is similar to that proposed for atherosclerosis [401.
Hyperlipidemia could contribute to enhanced delivery and
trapping of LDL in the matrix. Decreased cellular uptake of
glycated LDL in diabetes mellitus could increase the amount of
LDL remaining in the matrix. Expansion of mesangial matrix,
by whatever process, and formation of advanced nonenzymatic
glycation end-products of matrix components as in diabetes
mellitus would also increase the amount of LDL remaining in
the mesangium. This trapped LDL could then be subject to
oxidative modification, especially under conditions of local
activation of mesangial cells and monocytes, resulting in stim-
ulation of 12- and 15-lipoxygenase activity by these cells, which
causes oxidative modification of LDL [40, 56—59]. Lipid perox-
idation could also be enhanced by glucose in the presence of
trace amounts of transition metals [45, 46]. Peroxidation of
lipids accumulating in the matrix could in turn accelerate
crosslinking of nonenzymatically glycated matrix components
[60]. The Ox-LDL formed would be taken up by scavenger
receptors on monocytes, macrophages [61—63] and on mesan-
gial cells [28]. If larger amounts of Ox-LDL are formed, this
could result in cytotoxicity [28—30] and conditions that would
further favor formation of mesangial sclerosis. Thus, a cycle
could ensue whereby hyperlipidemia could contribute to the
development of glomerular sclerosis. Future work, including
demonstration of modified LDL in the mesangium, will be
required to validate this hypothesis.
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